Medapp

Medapp FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Medapp (MDA.WA) as of Nov 20, 2026 is -27.66 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 42.08 % — a change of -165.74% (lower).

FCF Conversion

-27.66 %

YoY

-165.74%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Medapp is 2025 -27.66 % . FCF Conversion Rate (FCF/EBITDA) of Medapp was 2024 42.08 % . It decreases by -165.74% lower compared to the previous year.

The Medapp FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
162.17 PLN
Jan 1, 2019
-589.73 PLN
Jan 1, 2020
-114.35 PLN
Jan 1, 2021
-16.42 PLN
Jan 1, 2022
-130.54 PLN
Jan 1, 2023
42.40 PLN
Jan 1, 2024
42.08 PLN
Jan 1, 2025
-27.66 PLN
The Medapp FCF Conversion history
YEARFCF ConversionYoY
-27.66 %-165.74%
42.08 %-0.78%
42.40 %-132.48%
-130.54 %+695.01%
-16.42 %-85.64%
-114.35 %-80.61%
-589.73 %-463.66%
162.17 %-25.68%
218.19 %+23.39%
176.84 %-3,055.78%
-5.98 %-236.11%
4.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medapp Stock analysis

What does Medapp do? MedApp SA generates revenue through its mobile marketing solutions in the medical field, primarily via the Carna Life software application. Carna Life functions as a telemedicine platform enabling doctors and patients to communicate, with features including data upload and download for test results, offline data review, and graphical statistics. The company serves healthcare providers and patients seeking telemedicine services, focusing on the Polish market through its Krakow headquarters. Moonrock Enterprise SA controls MedApp SA, leveraging its software for medical communication solutions. The firm's revenue model centers on the Carna Life application, which provides telemedicine services by facilitating secure data exchange between doctors and patients. Patients use the app to upload test results, while doctors interpret them through the platform, supported by offline functionality and data visualization tools. This system targets medical professionals and patients in Poland, operating within the telemedicine sector without external partnerships or additional branded products. MedApp SA's business relies solely on the Carna Life telemedicine system, which offers both online and offline modes for data management. The application includes statistics, visualizations, and tables for interpreted medical data, serving as a communication channel between healthcare providers and patients. Controlled by Moonrock Enterprise SA, the company monetizes its software through direct sales to medical institutions and patient users in the Polish healthcare market. Medapp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medapp stock

FCF Conversion Rate (FCF/EBITDA) of Medapp is -27.66 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Medapp changed from 42.08 % to -27.66 %, representing a -165.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Medapp since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Medapp with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Medapp

All Key Metrics — Medapp